1. Home
  2. MLTX
  3. MLTX News

Latest MoonLake Immunotherapeutics (MLTX) News on May 23, 2024

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

GlobeNewswire

7 days ago

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

Share on Social Networks: